Aziz Moqrich has been awarded the SATT IMPACT 2022 Prize for his team’s work on the TAFA4 Protein

.

Aziz Moqrich has been awarded the SATT IMPACT 2022 prize for his team’s work on the TAFA4 protein.

Dr Moqrich is a Research Director at the IBDM laboratory (part of CNRS, the French Centre National de la Recherche Scientifique) and co-founder of Tafalgie Therapeutics. The award recognizes his major discoveries, which have contributed to substantial advances in biology, and more specifically in pain research and associated innovative treatments.

SATT Sud-Est is the reference TTO (Technology Transfer Office) for Aix-Marseille University and CNRS unit The SATT was instrumental in the valorisation process of the work that led to the discovery of the TAFA4 protein’s therapeutic potential as a painkiller. This was achieved through several funding mechanisms as well as a series of administrative interventions with CNRS and AMU that facilitated the launch of Tafalgie Therapeutics. Notably, SATT Sud-Est managed the TAFA4 patent and its first license agreement with Tafalgie Therapeutics, in which SATT Sud-Est is one of the first investors.

During the awards ceremony, Aziz Moqrich presented his discovery of a new generation of non-opioid painkillers and Tafalgie Therapeutics’ work in this field.

Congratulations on this well-deserved honour! 




Visit our contact page